Genomic profiling is beginning to extend beyond the many applications in discovery research toward direct medical applications that hold the promise of more precise and individualized health-care delivery. There are many barriers and challenges that still need to be overcome before 'Precision Medical Genomics' can deliver the promise of more informed patient care, not the least of which is the unmet need for a new conceptual framework for recovering, understanding and translating potentially useful information from a single genome. Although a wide spectrum of scientific strategies, bioinformatic approaches, IT tools and knowledge resources have been developed to support discovery research, the interpretive requirements for recovering clinically useful insights from an individual's genome are different in many ways from those of traditional research goals. In this study, we compare and contrast the fundamental conceptual differences that distinguish 'research' to discover generalized knowledge from 'search' to recover individualized knowledge. We also consider the merits of applying evidence-based medicine and traditional scientific methods when n ¼ 1, and consider an alternative perspective based on a translational engineering approach and intelligence for interpreting genomic information from an individual case. Although the general idea of biological intelligence-based knowledge recovery that we introduce here can be broadly applied for personal genomics across many indications in medicine, we make a case that the need for adopting such a paradigm is greatest for supporting the management of complex diseases, and particularly suited for supporting therapeutic decisions in medical oncology. Early concepts for designing and implementing this kind of 'BioIntelligence' solution will be discussed. We also review the anticipated challenges of implementing genomic analysis and biological intelligence-based solutions in the practice of medical oncology by discussing some of the related pragmatic considerations for deploying the first generation of a 'Precision Medical Genomics' solution that can evolve and improve over time.
Introduction
'Where is the wisdom we have lost in knowledge? Where is the knowledge we have lost in information? ' TS Elliot Technological advances in genomic profiling continue to adhere to a Kursweilian trajectory (Kurzweil, 2005) showing exponential acceleration without any sign of slowing. The competition in the marketplace is fueling a very rapid evolution of genomic platforms, and the demand for a growing repertoire of basic and translational research applications is driving the emergence of ultrahigh-throughput next-gen technologies. The result is a continuous drop in the cost of genomic profiling, fueling a growing wealth of genomic data and the development of compendium IT solutions to facilitate everything from data processing and analysis to knowledge mining. All these innovations and trends also facilitate a broader dissemination of genomics and expansion beyond the laboratory. The past few years have seen a gradual but significant penetration of genomic profiling into health-care applications and even direct-to-consumer genomic services. The trend for genomic profiling beyond discovery research toward personal genomics applications is still a highly controversial movement (Kaye, 2008; Li et al., 2008; Brody, 2009) . There is currently no clear consensus in the scientific community that the associated risks and benefits justify the leap to extending the application of genomics beyond scientific study toward recreational and clinical arenas, but irrespective of these debates, the personal genomics train has left the station and many have now focused on efforts to create the compendium tools and resources to support this inevitability.
Genomic profiling will continue to generate an unprecedented quantity of data, and much of it is now published and openly available, but translation toward scientific and clinical impact is greatly lagging in comparison with data generation. The 'last mile problem' (a term coined by Dr Paul Meltzer (Guise et al., 2009) , which refers to the disconnect between the ability to leverage genomics to quickly drill down from the whole-genome level to a small handful of genes, and the time-and resource-consuming task of subsequently evaluating the functional or clinical role of those genes), is a major bottleneck for applying genomics in cancer research. In addition, we have not figured out how to fully extract the wealth of contextual information and meaning from the entire genomic profile, hence our translations are limited to applying wet-lab experiments to 'validate' one-off observations.
The development of powerful computational tools and bioinformatics resources has experienced an exponential growth over the last decade, which is largely driven by the need to manage an ever-increasing volume of genomic data and knowledge produced in the research sector. This increasing demand is also driving the commercial development of new research solutions that can both assist, through computational tools, to discover patterns in large data sets and, in knowledge mining, assist scientists in linking information to previous knowledge and thereby recover biologically useful insights. As important as the emerging bioinformatics tools and knowledge discovery strategies are for supporting basic and translational goals in discovery research laboratories, these strategies were not designed for supporting individualized medical genomic applications. In other words, statistically based strategies that leverage comparisons across multiple genomes cannot effectively be applied when n ¼ 1, and the goal is not knowledge discovery, but knowledge recovery. It is clear to those involved that trying to interpret a single genome will absolutely require the development and integration of innovative IT solutions, knowledge management resources and fresh strategies to intelligently translate genomic data. As we will explore later, understanding the unique requirements for personal genomics is key to developing the necessary informatics solutions.
The line between discovery research that will some day indirectly benefit future individuals and direct application of personal genomics to recover useful insights that can benefit the profiled individual is being redefined by hybrid initiatives such as the 'personal genome project' that aims to do both (Church, 2005) . The focus of these studies is on genomic and phenotypic profiling of individuals, but the data analysis is likely to be cross-sectional and leverages scientific approaches that try to uncover patterns across populations to make new generalized discoveries. Although these initiatives have an incredible 'greater good' potential, they nonetheless have only a limited direct benefit for the individuals who participate, with the hope that with time more people will participate, more knowledge will be generated and eventually there will be additional indirect benefits for the individuals who participate. These research initiatives are certainly necessary to accelerate discovery, but we argue that even if we had all the new discoveries that are anticipated to result from sequencing thousands of genomes, the discovery-based tools and data mining approaches that are currently available and the one-off validation of predictive markers are not suitable to effectively recover the more complex contextual insights encoded in an individual's genome. Consequently, genomic data are reduced to the consideration of the state of a small group of diseaserisk genes that provide marginal probabilistic information, which might have limited translational value for an individual. We lack a conceptual framework in which to process the rich individualized information more comprehensively, and an epistemological strategy to effectively leverage previously available and emerging knowledge to intelligently recover clinically relevant meaning and understanding from the complete information encoded in a single genome.
As we discuss below, there is a fundamental difference between research aimed at discovering new general knowledge and searching a single genome for known insights that apply to the specific individual. Dissecting and understanding this difference can guide the creation of new strategies to support a direct translation of single genomes. This lack of an intellectual framework on which to hang genomic knowledge is arguably one of the key bottlenecks that need to be resolved to better apply personal genomic information to inform more precise medical management of that individual.
Fundamental distinctions between research and search
Most applications of genomic profiling can be roughly categorized into one of two paradigms on the basis of the anticipated or desired outcome for analysis: (A) Research to Discover Generalized Knowledge; and (B) Search to Recover Individualized Knowledge.
(A) Research to Discover Generalized Knowledge is focused on investigating populations, and is exemplified by genome-wide association studies based on profiling of many individuals in a defined group or population. The key feature that distinguishes this category is that the analysis is focused on a confined study population, with the general intent of discovering associations that can be generalized beyond test subjects (additional details are outlined in Table 1 ). For example, genomic analysis in case-control studies has been a powerful approach for discovering critical genes that are either associated with a particular phenotypic trait, risk or causal mechanism of diseases. The underlying assumption is that the restricted subjects in the study group are sufficiently representative of the target population, so that associations discovered in the test group could be used to make probabilistic predictions about individuals who fall into the broader generalized target population. The predictive power and usefulness of the discovery depend on the strength of the association between genotype and phenotype; complicating and confounding variables (environmental exposures, lifestyle factors and so on); and the relative genetic and phenotypic homogeneity in the target population, as well as the size of the representative study group. With strong, uncomplicated genotype-phenotype relationships, reasonable representative cohorts can be used to discover predictive genetic factors. For complex disorders that are more heterogeneous in terms of confounding genetic events, and are influenced by environmental factors and show variable phenotypic expression, the associations may be difficult to discover and may require very large sampling to establish statistical significance (Klein, 2007) . With a few exceptions for very strong inherited genetic events that represent rare but highly penetrable risk factors for certain types of cancer, most sporadic cancers can be considered very complex multigenic, multifactorial diseases and population-based case-control genomic studies that aimed at discovering genetic events in the cancer genome associated with cancer risk or clinical behavior require a massive number of subjects in study cohorts. In addition, studies that attempt to leverage somatic cancer genomic analysis to discover new drug targets or discover predictive markers that can guide diagnosis, prognosis or therapeutic positioning are hampered by the inherent variability and complexity of the disease (Fox et al., 2009) .
Cancer genome researchers have applied many creative approaches to navigate the heterogeneity and complexity of the problem. One successful strategy is to reduce the number of variables and/or complexity by finding a related, and therefore more genetically uniform, study population. For example, using sibling pairs or family pedigrees to discover cancer risk alleles removes at least some of the confounding effects of genetic variation and focuses on a single genetic event shared in related cases of patients who are similarly affected (Smith et al., 1996; Schleutker et al., 2000; Powell et al., 2001) . Similarly, focusing the cohort to very well-defined subpopulations, in which some of the variation in phenotype-genotype variability is removed, can increase discovery power. When the question or hypothesis is not so clearly identified, and the goal of genomic analysis is more focused on discovering previously unknown disease elements, some researches have turned to a brute force approach in which very large consortia were built through very resourceintensive collaborative efforts to conduct genomic analyses across a very large number of cancer genomes (Varmus and Stillman, 2005) . Either way, the complexity and lack of control over variables increase substantially when one begins to apply profiling to clinical specimens to investigate the genomic features in sporadic cancer. In fact, Dr Edward Dougherty is on record for stating that we have a crisis in epistemology, critically questioning the study design, methods and validity of inferences in published literature (Dougherty, 2008) . The critical challenges associated with statistical methods to analyse sporadic cancer genomes to discover significant associations, patterns and features from structural and functional genomics data using crosssectional or longitudinal study designs are beyond the scope of this study. Instead, we turn our attention to the challenge of searching a single genome with the goal of gaining some intelligent insights and understanding.
(B) The alternative paradigm for genomic profiling aims to 'Search to Recover Individualized Knowledge'. In contrast to the former, this paradigm encompasses applications focused on investigating an individual, for the purpose of extracting existing knowledge with individualized relevance to the person being analysed. The insights recovered from such an analysis represent the fruits of mining previous knowledge to assist in the interpretation of a specific cancer genome, and the resulting insights recovered are, by design, pertinent to the person being analysed, without any general claim to anyone else. Precision Medical Genomics (PMG) uses this approach to directly guide medical care, and exemplifies a new emerging paradigm for genomic profiling. A subtle but fundamental difference is that typical discovery research studies involve the analysis of a representative test group of individuals to discover knowledge that can be further tested, validated and then applied to make predictions about future individuals beyond the test group. PMG is focused on profiling a single person (n ¼ 1) and must therefore apply an alternative data analysis approach to directly interpret the results of a single interrogated genome, with the intention of translating the recovered insights to guide the medical management of the same individual. As already alluded to by us, a comprehensive scientific method to interpret and understand genomic results from an individual sufficiently well enough to make useful medical decisions has not yet been fully developed. Nonetheless, several pioneering for-profit companies now offering direct-to-consumer genomic profiling trail blaze forward by using conventional statistically based strategies to assign probabilities of phenotype expression to help an individual interpret his or her own genomic information. The hope is that the evolving annotation of the human genome and the development of better informatics tools will make these genomic profiles increasingly more useful. There is therefore a clear and timely need to begin conceptualizing the 
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'next generation' scientific framework and knowledge management IT solutions to support translating complex genomic data from an individual into clinically useful insights. More importantly, the rigor for showing significant clinical benefit will require a truly robust informatics solution before personal genomics can be effectively transferred into health care. Toward that end, we began to envision an approach that leverages biological intelligence (BioIntelligence) to relate specific events to each other (connect the dots), build a higherlevel concept from elemental data and thereby enable recovering of the best possible understanding from an individual's genomic information. Framing the problem under a new perspective with a vision of a translational engineering approach based on biological intelligence will enable the 'search' for meaning in genomic profiles.
Defining biointelligence
A critical aspect of the vision we propose here is the concept of applying an engineering approach to intelligence for the interpretation of genomic data, and, at this point, we will define and distinguish this approach from statistical approaches currently applied in data mining. For the purpose of our discussion, we define intelligence as the capacity to reason, especially as it applies to the ability to apply learned knowledge to interpret and understand something new and unknown. Any intelligence would therefore require some previous learning of knowledge: that knowledge must be stored in a way that it can be accessed and compared with any new input. Both biological and computational reasoning can be viewed as algorithmic rules to compare and relate stored information to some input (new unknown information). The result of applying reasoning in this way would be a meaningful prediction. Iterative cycles of searching for rule-based hits; making predictions to characterize the unknown; and testing of prediction by searching for related inputs can lead to some convergence on an optimized prediction, which we will call understanding. This definition implies that it could be synthetically reproduced in machines, and it would be reasonable to expect that this is something that modern computational science and software engineering should be able to achieve. In fact, a wide spectrum of mathematical modeling and computational strategies have been applied to create computer algorithms that can be artificially trained with previous knowledge, and then tested for their capacity to intelligently recognize an unknown input. When the input is not complicated and can be unambiguously matched to a previously learned pattern, and all possible variable inputs can be simply and comprehensively modeled, machines can simulate intelligent recognition and prediction. When it comes to recognizing variable and/or complex inputs, however, especially when the entire universe of possible variations cannot be computed, modeled or learned, even the simplest tasks, such as distinguishing the difference between a cat and a dog in an image, cannot be achieved using conventional computational approaches.
The human brain has no problem in performing incredible feats of searching complex inputs and in extracting an accurate and meaningful understanding, even if the specific input is drastically different from anything that has previously been encountered, remembered or imagined. What is biological intelligence doing that artificial intelligence lacks? Arguably, computers can store and process large volumes of data, but they do not even approach the vast capacity of the network of neurons in the human brain. However, the difficulties in artificial intelligence suggest that capacity is only a part of the problem, and there may be fundamental deficiencies in our approach to computationally represent knowledge, and perhaps the answers to AI reside in a better understanding of biological intelligence. Jeff Hawkins and other cognition scientists have inspired a movement in computer science to explore the idea that it is the multilayered structure of the neocortex and the hierarchical organization of learned knowledge that make biological intelligence so much more powerful and effective than our current attempts at artificial intelligence (Hawkins and Blakeslee, 2004) . The biological organization of hierarchical storage of learned knowledge (memory) is based on a multilayer flow of information that begins with the lowest level inputs, which are represented by elemental signals. A group of input signals might activate multiple nodes at the lowest level, which are then projected upward to converge on a single node in the second level. This higher node represents a pattern of multiple signals. Subsequently, multiple pattern nodes in the second level could converge and trigger a single node in the third level, which represents a pattern of patterns. The next level would represent patterns of patterns of patterns, and so on. This is of course not how our computer memory is organized, but early work on developing algorithms that leverage a three-layer hierarchical memory structure performs tasks that were not previously possible using any other pattern recognition approach. Clearly, this pioneering work to leverage our understanding of cognitive function can be extremely powerful in building machines that begin to achieve tasks that require intelligence, and these breakthrough advances in AI are anticipated to have a major impact on our ability to interpret and understand complex molecular data.
However, we do not have to wait for intelligent machines to be available, before we can apply the lessons learned from how biology achieves intelligence (BioIntelligence). In fact, many of the recent innovations in semantic data representation provide us with a framework for a very similar approach to a hierarchical organization of information, in which data could be linked at various levels, beginning with elemental measurements up to higher-level patterns of measurements that have some contextual meaning and further up to higher-level groups of patterns that represent higher-level concepts. Semantic web technologies and standards provide tools for building these ontological relationships and storing knowledge in a frame work that facilitates semi-automated approaches to intelligently search new input for some meaningful annotation. Again, we do not envision an algorithm that will turn a set of whole cancer genome-sequencing measurements into an understanding of which drug might be best suited for that patient. Instead, the available tools, ontologies and knowledge resources can be strategically integrated to organize all available previous knowledge into an ontologically organized structure that could be then used to map data from an individual's genome and link it to higher-level concepts. This hierarchical organization (as illustrated in Figure 1 ) will enable an expert to search and recover connections between genetic events and higher-level insights into contextual vulnerabilities to therapeutics that might not be direct or obvious, but are nonetheless intelligently linked. In our own laboratory, we leverage more than 300 different knowledge management and mining tools and resources to support the manual task of interpreting single genomes. We are also putting into place hierarchical knowledge representation strategies that enable the recovery of the indirect links between gene states and drugs. Below, we review some of these innovations in the context of Precision Medical Genomics.
Translational engineering strategies to enable search and recovery of individualized knowledge
Today, the process of interpreting genomic profiling data from a single individual to extract clinically useful insights that can guide individualized therapy is carried out using a hybrid approach (manually with computational assistance) by knowledge recovery/mining experts. This relies very heavily on human reasoning and expert curation. These experts use a wide spectrum of sophisticated computational knowledge-mining resources for intelligently applying their own previous experience and collective available knowledge resources to extract a meaningful understanding of how the information could be translated for patient benefit. The end results of this kind of knowledge mining can be simple prioritization of individual observations that have intrinsic value or meaning, but they can also be more sophisticated coherent contextual interpretations that infer unique insights to support tailored interventions. The need to interpret genomic information is growing rapidly, and the current hybrid approach suffers from lack of scalability, speed and rigor in methodology. More importantly, the increasing depth, dimensionality and complexity of genomic data, along with the rapidly growing trend toward personal genomics, will be greatly hindered without a comprehensive solution to the interpretation bottleneck.
There are a wide variety of genomic platform technologies and they produce disparate data types, all of which are potential inputs for interpretation. The major challenge in recovering knowledge from such complicated inputs is finding a strategy to represent information in a way that it could be linked to other information. Semantic Web standards and technologies offer an attractive solution for data integration and representation to enable effective knowledge recovery solutions. The semantic web is a new initiative for Figure 1 A hierarchically organized and ontologically based, knowledge representation solution to support intelligent navigation of genomic information. Previous knowledge can be graphed on a hierarchically organized ontology graph. Once an ontology graph is mapped, it can be used (1) by starting at the bottom with detailed contextual genetic information and projecting upward to search and recover clinically relevant phenotypes, or (2) by starting at the top asking a research question about a specific phenotype and projecting down to discover associated patterns of genetic events.
providing a common framework for information representation to link data-enabled sharing and recovery across applications and community boundaries. The application of such strategies enables integration of inputs from different platforms, and also enables connecting data to previous knowledge. There are currently various initiatives within the academic and pharmaceutical sector leveraging semantic web technologies for data representation and interpretation. For example, Eli Lilly has begun implementing semantic web principles to construct systems to enable scientists to link and discover relevant information across disparate data sources (Manning et al., 2009 ). In addition, efforts have begun that leverage semantic web-based principles for designing systems to elucidate nonobvious information for novel treatment recommendations and identification of candidate disease genes and contexts (Ruttenberg et al., 2007; Chen et al., 2009; Qu et al., 2009) . Figure 2 illustrates how these disparate inputs might be integrated and flow into a hierarchically based semantic framework, and translated into metadata representations of a patient, which can then be used to search for individualized therapeutic options.
Applying search for research
The knowledge recovery strategies and knowledge mining approaches considered here are intentionally focused on their application to facilitate the 'search' for meaning in interpreting personal genomes for the purpose of making oncology practice more precise. These intelligence-based strategies and knowledgeengineering technologies also have a clear role in Figure 2 An illustrative example of how multidimensional genomic and clinical data can be mapped and projected upwards through an ontology graph to search through previous knowledge and intelligently recover the individualized therapeutic options. Patient-specific data from clinical and molecular profiling analysis flows into a comprehensive EMR where it is captured, processed and mapped into specialized databases in the horizontal search space. The databases have internal and external relations in the horizontal plane and orthogonally linked out to each other, and vertically to higher-level concepts in the vertical ontology layer. This facilitates more intelligent direct and indirect connections between drug, gene states and clinical data (through mapping upwards to higher-level concepts) even if there is no direct link in the search space. The example above shows simplified patient-specific data to illustrate the kinds of direct links in the horizontal layer and the vertical mapping to recover concepts and coherent contexts that infer therapeutic options indirectly from the ontology. This figure is a modification of the original illustration created by Meraj Aziz.
accelerating discovery 'research'. This is especially true in pharmacogenomics studies to discover genetic determinants of drug response and oncogenomics studies to discover new drug targets. BioIntelligence solutions applied to discover research approaches can be distinguished from traditional bioinformatic approaches to genomic research studies. Intelligent search applied to recover higher-level concepts and insights would focus on the understanding of data from a single individual first, and then the intelligence gained can be crossreferenced across a cohort of multiple individuals in a population to discover generalized knowledge. In our experience, cancer genomes are highly variant at the granular level of the gene state, but applying the biointelligence approach for knowledge recovery individually and then comparing the contextual vulnerabilities across the population provide a powerful and complementary approach to traditional statistically based analyses.
Conceptually, research can build on previous knowledge, but it is not dependent on it. New discoveries can certainly be made using statistical approaches to find previously unknown patterns across a defined set of cancer genomes. For example, it is possible to discover a mutation in a previously unknown gene with an unknown function and associate that genetic event to resistance to a specific cancer drug. Conversely, recovering insights from an individual genome is greatly dependent on, and limited by, the availability and access to previous knowledge. In other words, observing the same mutation for the first time in an individual cannot be leveraged to guide the use of a specific drug until there is sufficient previous knowledge about what the gene does, how the mutation might affect that gene and what impact that might have on the sensitivity to a particular drug. In some cases, the critical mass of previous knowledge will be sufficient to recover an understanding, even though the observed event has never been seen before or linked to drug sensitivity. In that regard, BioIntelligence makes it possible to understand isolated events that have not been observed before, and this could in turn lead to the generation of novel hypotheses that can then be subsequently tested to generate potentially generalized knowledge.
Implementation challenges for biointelligence
The recent explosion in cancer genome profiling has generated an unprecedented depth and dimensionality of personalized clinical information and sophisticated molecular measurement data. These genomic analyses are typically conducted as part of a discovery research project to either identify new drug targets, predictive markers or gain insights into mechanisms of disease or drug response. As new knowledge about gene function, interaction and role in cellular concepts, it will be increasingly useful to define and leverage these more comprehensive contexts to uncover useful insights that can guide therapeutic selection. Besides the increasing complexity of multidimensional molecular data, genomics-guided therapeutics are further complicated by the ever-growing selection of new and emerging pharmaceutical products. Taken together, these advances have the potential to revolutionize oncology health care and usher in a new era of 'Information Based Medicine'. Unfortunately, the medical community is already overwhelmed with the complexity of all this information. In addition, there is currently no simple solution for translating this complex information into a recommendation to support their choice of therapeutic options from the rapidly growing selection of new drugs. This growing problem transcends almost all medical areas, but is by far the most urgent and critical in oncology, in which the choice of drug treatment for end-stage cancer patients who have exhausted the standard lines of therapy is typically decided in an ad hoc manner. Consequently, the power of molecular profiling and latest pharmaceutical insights are not readily being leveraged for individualized treatment or being translated into patient benefit.
The challenge of enabling oncologists with the ability to leverage molecular information from genomic profiling of their patients, and the most relevant available biomedical knowledge to extract the most useful therapeutic insights, also requires consideration of how decisions are currently made. There are least four key factors that currently help inform and influence an oncologist's selection of cancer drugs: (1) their knowledge-mining skills in finding and understanding relevant information; (2) access to professional peers with experience with and insights into similar cases; (3) clinical oncologists' personal experience with similar cases; and (4) their willingness and opportunity to spend time and effort in interpreting and mining complex individualized genomic profiles and researching disparate information sources to gain useful insights for each case. Although new medical informatics tools from commercial and public sources that have been developed over the last decade greatly improve access to information, thereby enabling oncologists to retrieve the latest peer-reviewed papers and information from trusted sources, understanding and interpreting the growing density and complexity of available information have outpaced the development of tools. In other words, access to useful information is rate limited by tools to access and recover knowledge and insights from data. This complexity is increasingly becoming a major bottleneck in leveraging the ability of genomic information of any kind to support personalized therapy. Consequently, the ever-growing amount of available information about patients' disease and the massive amounts of pharmaceutical insights are not effectively being leveraged to get the right drugs to the right patients.
To address this important unmet need in translating complex information into individualized drug recommendations, a simple search tool is envisaged that can match genomic contexts to available drug selections. It is important to note that such a strategy is not dependent on very comprehensive inputs or on extremely sophisticated knowledge extraction software.
Similar to the earlier version of web search engines, simple inputs and simple text matching can in itself begin to serve immediate needs. As the molecular and genomic data inputs become more complex, and a BioIntelligence paradigm emerges and enables effective and efficient recovery of useful insights from complex data, the search engine approach to accessing these insights will improve. Implementing such an online service can therefore evolve and engage the oncology community to evolve as needs develop.
The ultimate vision is to provide useful information management and knowledge recovery tools through an online portal that provides access to retrieve trusted knowledge that can be used to support smarter therapeutic decisions. A key feature of such a service must be scalability to deal with increasing complexity of input while maintaining an absolute simplicity of output. In other words, as the depth and dimensionality of pharmacological information grows and the complexity of patient-specific input also increases, the search output will continue to be a useful list of recommended drugs, and will only improve in relevance ranking. As the search result is generated in a matter of seconds and prioritized for relevance using sophisticated algorithms that understand the relationships between patientspecific parameters and pharmacological insights, a physician needs to only click through the drug information links, quickly review the molecular context of vulnerability evidence used to prioritize a particular drug and determine whether the information is useful to support a therapeutic decision. As challenging as it may seem to develop and implement the required computational tools and knowledge resources to recover a clinically useful understanding from individual cancer genomes, the vision of taking a more translational engineering approach based on biological intelligence provides some hope that deploying the basic framework will enable an environment capable of driving rapid learning and evolution based on use. The challenge is to get the snowball rolling, and initiate this iterative cycle of search and research.
Outlook for deploying precision medical genomics
Selection of a strategy to navigate the complexity of the cancer genome is very much dependent on whether the intention is to search or research. In comparing and contrasting 'search' and 'research', we revealed differences in the requirements and outcome for each approach. Despite the fundamental differences between search and research, we show that engineering-based strategies for BioIntelligence are both dependent on and complementary to traditional discovery research strategies. Most importantly, lessons learned from knowledge representations in biological intelligence will help advance both search and research applica tions. We can anticipate that electronic medical records and personal health record solutions will provide opportunity for health-care providers to organize and gather the collective experience of applying 'Precision Medical Genomics'. As cumulative information from clinical and molecular profiling is captured and linked using hierarchical semantic frameworks, it will provide the possibility of putting this linked data into a BioIntelligence learning environment, in which outcome data can be computationally captured. From a research perspective, the growing trust of collective knowledge and experience can enable the application of computational modeling across a growing number of individuals, who can be represented by higher-level metadata descriptors (see Figure 1) , and thereby binned into welldefined populations. Over time, incorporating computational intelligence engines into the system will enable collective experience to be integrated into the ontology graph by iteratively integrating learned relationships between gene states, concepts and pharmacological outcome to provide an even more intelligent interpretation for the next case. By priming and evolving the system with experience to improve the BioIntelligence solutions, the overall clinical value proposition for genomic profiling increases, which will in turn drive more cases into the system and provide larger cohorts of cases for discovery research and so on.
The availability of previous knowledge and more complete molecular ontological resources will of course be required to prime the system, and similar to any intelligence-based system, learning will be the ratelimiting step in the early deployment of this paradigm. The availability of existing previous knowledge in the public domain represents an embryonic starting point for the learning process, which of course can already be applied in a semi-automated manner to support medical genomics. In fact, oncologists are very eager to use online knowledge services to help them search the latest knowledge resources to better understand the meaning of the molecular data they have at hand (De Leo et al., 2006) . This is especially true in cases in which patients have failed to respond to conventional and obvious therapeutic options, and oncologists are eager to recover patients using more individualized treatment options. Pioneering efforts to bring this strategy to the clinic have been reported elsewhere (Von Hoff et al., 2009 ) and have clearly indicated that using molecular profiling to inform therapeutic options does in fact reveal useful therapeutic options that bring significant benefit to the patient. The challenge, moving forward, will be to go beyond these important clinical trials that clearly establish proof of concept for personal genomics, and begin to actually implement, disseminate and transition the 'Precision Medical Genomics' strategy from clinical research arena to the practice of medicine, where the paradigm could naturally evolve over time. In the early stages of applying personal genomics paradigms, it is easy to get sidetracked on clinical studies focused on generating generalized evidence for the application of methods and strategies, and to focus intentions on the tangential goals of leveraging collective genomic profiling experience to support research discovery that will generalize benefits for future patients and society. Critical to the pragmatic deployment of this paradigm is the assurance that the primary purpose for applying genomic profiling and the subsequent search to recover useful insights from that individual genome are focused on bringing benefit to the individual being profiled.
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